NYMX Stock Price, News & Analysis

Nymox Pharmaceutical Corporation (symbol: NYMX) is a biopharmaceutical company dedicated to the research and development of innovative drugs targeting the aging population. Founded in 1989 and headquartered in Nassau, Bahamas, Nymox operates internationally, including in Canada, the United States, and Europe.

The company's lead drug candidate, Fexapotide Triflutate (NX-1207), is designed to treat benign prostatic hyperplasia (BPH). Having successfully completed Phase III clinical trials, NX-1207 is now in Phase II trials for treating low-grade localized prostate cancer and is also undergoing preclinical studies for hepatocellular carcinoma.

Nymox offers several diagnostic products, such as Nicalert and TobacAlert test strips, which use urine or saliva to detect nicotine and tobacco product use. Another significant product is Alzheimalert, a proprietary urine assay that helps physicians diagnose Alzheimer's disease.

Recently, Nymox made headlines with the issuance of several important U.S. patents for NYMOZARFEX, showcasing significant progress in their research efforts. The latest studies indicate that a minimal treatment of 15 mg NYMOZARFEX leads to a significant long-term reduction in prostate cancer surgeries and radiotherapies for patients with low-grade prostate cancer.

With a commitment to advancing healthcare solutions for an aging demographic, Nymox Pharmaceutical Corporation continues to be at the forefront of biopharmaceutical innovation, making impactful strides in the detection and treatment of age-related diseases.